Plain-English translation of NCT07229768 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new treatment called , which is a radioactive injection designed to target and treat advanced cancers that have spread or cannot be surgically removed. Researchers want to understand how safe this medication is, how your body processes it, and whether it can help slow or shrink your cancer. You would be among the first patients to receive this treatment.
Standard cancer treatments don't work for everyone, and some patients run out of options or can't tolerate existing therapies. This medication represents a new approach that may help patients whose cancers have stopped responding to conventional care.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the experimental medication and undergo imaging scans (including PET/CT scans) to monitor how your body responds and whether your tumors shrink. The trial will also track your blood work and organ function regularly to ensure the treatment is safe. This is a small early-stage study enrolling only about 4 patients at a single center, so you would receive close medical supervision throughout the process.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Yan Xing
Enrollment target
~4 participants
Started
October 2025
Primary completion
November 2026
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yan Xing
Yan Xing
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.